• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膜性肾病的新型生物标志物。

Novel Biomarkers in Membranous Nephropathy.

机构信息

Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, China.

Department of Laboratory Medicine, Beijing Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing, China.

出版信息

Front Immunol. 2022 Apr 22;13:845767. doi: 10.3389/fimmu.2022.845767. eCollection 2022.

DOI:10.3389/fimmu.2022.845767
PMID:35529848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9074781/
Abstract

Membranous nephropathy (MN) is the main cause of adult nephrotic syndrome (NS). The pathogenesis of MN is complex and involves subepithelial immune complex deposition. Approximately one-third of patients with MN develop end-stage renal disease (ESRD). Timely diagnosis and reasonable intervention are the keys to improving prognosis. In recent years, with the development of high-throughput technologies, such as mass spectrometry (MS), microarray, and sequencing technologies, the discovery of biomarkers for MN has become an important area of research. In this review, we summarize the significant progress in biomarker identification. For example, a variety of podocyte target antigens and their autoantibodies have been reported. Phospholipase A2 receptor (PLA2R) is the most well-established target antigen in MN. PLA2R and its autoantibodies have clinical significance, with both diagnostic and therapeutic value for MN. In addition, a variety of new biomarkers, including proteins, metabolites, noncoding RNAs (ncRNAs), and immune cells, have recently been found. These MN-related biomarkers have great significance in the diagnosis, progression, prognosis, and treatment response of MN.

摘要

膜性肾病(MN)是成人肾病综合征(NS)的主要病因。MN 的发病机制复杂,涉及上皮下免疫复合物沉积。约三分之一的 MN 患者发展为终末期肾病(ESRD)。及时诊断和合理干预是改善预后的关键。近年来,随着高通量技术(如质谱(MS)、微阵列和测序技术)的发展,MN 生物标志物的发现已成为研究的重要领域。在这篇综述中,我们总结了生物标志物鉴定的重要进展。例如,已经报道了多种足细胞靶抗原及其自身抗体。磷脂酶 A2 受体(PLA2R)是 MN 中最成熟的靶抗原。PLA2R 及其自身抗体具有临床意义,对 MN 具有诊断和治疗价值。此外,最近还发现了多种新的生物标志物,包括蛋白质、代谢物、非编码 RNA(ncRNA)和免疫细胞。这些与 MN 相关的生物标志物在 MN 的诊断、进展、预后和治疗反应中具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/c3f87b51371e/fimmu-13-845767-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/54eee695de8a/fimmu-13-845767-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/41be02a1176e/fimmu-13-845767-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/c3f87b51371e/fimmu-13-845767-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/54eee695de8a/fimmu-13-845767-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/41be02a1176e/fimmu-13-845767-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caca/9074781/c3f87b51371e/fimmu-13-845767-g003.jpg

相似文献

1
Novel Biomarkers in Membranous Nephropathy.膜性肾病的新型生物标志物。
Front Immunol. 2022 Apr 22;13:845767. doi: 10.3389/fimmu.2022.845767. eCollection 2022.
2
Membranous nephropathy-diagnosis and identification of target antigens.膜性肾病——诊断和靶抗原鉴定。
Nephrol Dial Transplant. 2024 Mar 27;39(4):600-606. doi: 10.1093/ndt/gfad227.
3
Circulating antibodies to α-enolase and phospholipase A receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy.日本原发性或继发性膜性肾病患者中抗α-烯醇化酶和磷脂酶A受体的循环抗体及肾小球沉积物的组成
Clin Exp Nephrol. 2017 Feb;21(1):117-126. doi: 10.1007/s10157-016-1235-2. Epub 2016 Feb 1.
4
Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.加速严重膜性肾病患者循环抗磷脂酶 A2 受体抗体的耗竭:双重滤过血浆置换和奥法妥木单抗的初步发现。
Nephron. 2020;144(1):30-35. doi: 10.1159/000501858. Epub 2019 Jul 23.
5
A comprehensive narrative review of diagnostic biomarkers in human primary membranous nephropathy.人类原发性膜性肾病诊断生物标志物的全面叙述性综述。
Biomark Med. 2017 Sep;11(9):781-797. doi: 10.2217/bmm-2017-0081. Epub 2017 Sep 11.
6
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.抗 M 型磷脂酶 A2 受体 (PLA2R) 自身抗体在鉴别特发性膜性肾病 (IMN) 与继发性及其他肾小球疾病中的诊断特异性。
J Nephrol. 2018 Apr;31(2):271-278. doi: 10.1007/s40620-017-0451-5. Epub 2017 Oct 28.
7
[Modern view on the complement system role in membranous nephropathy].[关于补体系统在膜性肾病中作用的现代观点]
Ter Arkh. 2022 Aug 4;94(6):772-776. doi: 10.26442/00403660.2022.06.201563.
8
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis.抗中性粒细胞胞浆抗体相关性肾小球肾炎伴髓过氧化物酶和磷脂酶 A2 受体在膜性肾病病变中的检测:两例显微镜下多血管炎患者的报告。
BMC Nephrol. 2018 May 23;19(1):120. doi: 10.1186/s12882-018-0922-5.
9
[Membranous nephropathy].[膜性肾病]
Rev Prat. 2021 Jan;71(1):85-89.
10
Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.特发性膜性肾病和非典型膜性肾病患者血清甘露糖结合凝集素、抗磷脂酶 A2 受体抗体与肾脏结局的相关性:一项单中心回顾性队列研究。
Ren Fail. 2022 Dec;44(1):428-433. doi: 10.1080/0886022X.2022.2048016.

引用本文的文献

1
Inflammation-related lncRNAs in the regulation of kidney injuries; special emphasis on novel lncRNA-based delivery platforms.炎症相关长链非编码RNA在肾脏损伤调节中的作用;特别强调基于新型长链非编码RNA的递送平台。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep 1. doi: 10.1007/s00210-025-04516-x.
2
Detection and prognostic relevance of PLA2R epitopes in idiopathic membranous nephropathy: a simultaneous quantitative multiplex suspension array detection method.特发性膜性肾病中PLA2R表位的检测及其预后相关性:一种同步定量多重悬浮阵列检测方法
Clin Kidney J. 2025 Jan 13;18(3):sfaf010. doi: 10.1093/ckj/sfaf010. eCollection 2025 Mar.
3

本文引用的文献

1
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
2
Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy.丝氨酸蛋白酶HTRA1作为原发性膜性肾病中的一种新型靶抗原。
J Am Soc Nephrol. 2021 Jul;32(7):1666-1681. doi: 10.1681/ASN.2020101395. Epub 2021 May 5.
3
Protocadherin 7-Associated Membranous Nephropathy.原钙黏蛋白 7 相关膜性肾病。
Impact of immune cell metabolism on membranous nephropathy and prospective therapy.
免疫细胞代谢对膜性肾病的影响及前瞻性治疗
Commun Biol. 2025 Mar 10;8(1):405. doi: 10.1038/s42003-025-07816-3.
4
Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments.靶向乙型肝炎病毒相关性肾病:当前抗病毒治疗的疗效与挑战
Clin Exp Med. 2025 Feb 15;25(1):57. doi: 10.1007/s10238-025-01584-4.
5
Integrated bioinformatics analysis for identifying fibroblast-associated biomarkers and molecular subtypes in human membranous nephropathy.用于鉴定人类膜性肾病中成纤维细胞相关生物标志物和分子亚型的综合生物信息学分析
Heliyon. 2024 Sep 25;10(21):e38424. doi: 10.1016/j.heliyon.2024.e38424. eCollection 2024 Nov 15.
6
Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy.血清 BAFF 水平与特发性膜性肾病的预后相关。
Ren Fail. 2024 Dec;46(2):2391069. doi: 10.1080/0886022X.2024.2391069. Epub 2024 Aug 14.
7
Future embracing: exosomes driving a revolutionary approach to the diagnosis and treatment of idiopathic membranous nephropathy.拥抱未来:外泌体推动特发性膜性肾病诊断和治疗的革命性方法。
J Nanobiotechnology. 2024 Aug 8;22(1):472. doi: 10.1186/s12951-024-02633-y.
8
Proteomic analysis of glomeruli, tubules and renal interstitium in idiopathic membranous nephropathy (IMN): A statistically observational study.特发性膜性肾病(IMN)肾小球、肾小管和肾间质的蛋白质组学分析:一项统计学观察性研究。
Medicine (Baltimore). 2023 Dec 15;102(50):e36476. doi: 10.1097/MD.0000000000036476.
9
THSD7A as a Promising Biomarker for Membranous Nephrosis.THSD7A 作为膜性肾病有前途的生物标志物。
Mol Biotechnol. 2024 Nov;66(11):3117-3135. doi: 10.1007/s12033-023-00934-5. Epub 2023 Oct 26.
10
Towards the Definition of the Molecular Hallmarks of Idiopathic Membranous Nephropathy in Serum Proteome: A DIA-PASEF Approach.朝着定义特发性膜性肾病血清蛋白质组分子特征标志物的方向努力:一种 DIA-PASEF 方法。
Int J Mol Sci. 2023 Jul 21;24(14):11756. doi: 10.3390/ijms241411756.
J Am Soc Nephrol. 2021 May 3;32(5):1249-1261. doi: 10.1681/ASN.2020081165. Epub 2021 Apr 8.
4
Altered expression of serum miR-106a, miR-19b, miR-17, and PTEN in patients with idiopathic membranous nephropathy.特发性膜性肾病患者血清 miR-106a、miR-19b、miR-17 和 PTEN 的表达改变。
J Clin Lab Anal. 2021 Apr;35(4):e23737. doi: 10.1002/jcla.23737. Epub 2021 Mar 21.
5
Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy.Th17/Treg 比值改变作为特发性膜性肾病发病机制的一种可能机制。
Cytokine. 2021 May;141:155452. doi: 10.1016/j.cyto.2021.155452. Epub 2021 Feb 8.
6
Advances in Membranous Nephropathy.膜性肾病的进展
J Clin Med. 2021 Feb 5;10(4):607. doi: 10.3390/jcm10040607.
7
In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes.在膜性狼疮肾炎患者中,外生骨疣阳性和外生骨疣阴性代表两种不同的表型。
J Am Soc Nephrol. 2021 Mar;32(3):695-706. doi: 10.1681/ASN.2020081181. Epub 2021 Jan 21.
8
Differential Expression of Urinary Exosomal Small RNAs in Idiopathic Membranous Nephropathy.特发性膜性肾病患者尿外泌体小分子 RNA 的差异表达。
Biomed Res Int. 2020 Dec 29;2020:3170927. doi: 10.1155/2020/3170927. eCollection 2020.
9
New 'Antigens' in Membranous Nephropathy.膜性肾病中的新“抗原”。
J Am Soc Nephrol. 2021 Feb;32(2):268-278. doi: 10.1681/ASN.2020071082. Epub 2020 Dec 30.
10
Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy.THSD7A抗体对特发性膜性肾病诊断效能的Meta分析
Glob Chall. 2020 Sep 6;4(11):1900099. doi: 10.1002/gch2.201900099. eCollection 2020 Nov.